000963 华东医药
已收盘 12-19 15:00:00
资讯
新帖
简况
翰森制药与默沙东达成20亿美元合作,恒瑞医药1类新药获批临床,华东医药1类新药获美FDA批准临床
谈医说药 · 12-18 23:06
翰森制药与默沙东达成20亿美元合作,恒瑞医药1类新药获批临床,华东医药1类新药获美FDA批准临床
华东医药(000963.SZ):HDM1005注射液药品临床试验申请获得美国FDA批准
智通财经 · 12-18 17:28
华东医药(000963.SZ):HDM1005注射液药品临床试验申请获得美国FDA批准
华东医药(000963)106.37万股限售股将于12月16日解禁,占总股本0.06%
证券之星 · 12-16
华东医药(000963)106.37万股限售股将于12月16日解禁,占总股本0.06%
华东医药(000963.SZ):注射用利纳西普用于治疗复发性心包炎上市许可申请获批准
智通财经 · 12-10
华东医药(000963.SZ):注射用利纳西普用于治疗复发性心包炎上市许可申请获批准
华东医药最新公告:全资子公司收到注射用利纳西普药品注册证书
证券之星 · 12-10
华东医药最新公告:全资子公司收到注射用利纳西普药品注册证书
华东医药:关于监事辞职暨补选监事的公告
新浪财经-鹰眼工作室 · 12-04
华东医药:关于监事辞职暨补选监事的公告
概念掘金 | 医药巨头在华新建胰岛素生产基地,这些公司或成为“赢家”
格隆汇 · 12-03
概念掘金 | 医药巨头在华新建胰岛素生产基地,这些公司或成为“赢家”
华东医药(000963.SZ):乌司奴单抗注射液用于儿童斑块状银屑病的补充申请获受理
智通财经 · 12-02
华东医药(000963.SZ):乌司奴单抗注射液用于儿童斑块状银屑病的补充申请获受理
华东医药最新公告:乌司奴单抗注射液儿童斑块状银屑病补充申请获受理
证券之星 · 12-02
华东医药最新公告:乌司奴单抗注射液儿童斑块状银屑病补充申请获受理
华东医药(000963.SZ):中美华东部分产品纳入国家医保目录
智通财经 · 11-29
华东医药(000963.SZ):中美华东部分产品纳入国家医保目录
《股市简讯》中国华东医药劲扬超7%,子公司获得FDA新药临床试验批准通知
路透中文 · 11-29
《股市简讯》中国华东医药劲扬超7%,子公司获得FDA新药临床试验批准通知
华东医药(000963.SZ):中美华东HDM1005注射液获得美国FDA新药临床试验批准
智通财经 · 11-28
华东医药(000963.SZ):中美华东HDM1005注射液获得美国FDA新药临床试验批准
华东医药最新公告:全资子公司中美华东获得美国FDA新药临床试验批准
证券之星 · 11-28
华东医药最新公告:全资子公司中美华东获得美国FDA新药临床试验批准
11月28日华东医药现1笔大宗交易 机构净买入204.4万元
证券之星 · 11-28
11月28日华东医药现1笔大宗交易 机构净买入204.4万元
华东医药两款创新药获批上市
市场资讯 · 11-28
华东医药两款创新药获批上市
《股市简讯》杭州九源基因香港“首秀”急挫四成,尽管公开发售超额675倍
路透中文 · 11-28
《股市简讯》杭州九源基因香港“首秀”急挫四成,尽管公开发售超额675倍
华东医药(000963.SZ):IM19嵌合抗原受体T细胞注射液药品注册上市许可申请获受理
智通财经 · 11-27
华东医药(000963.SZ):IM19嵌合抗原受体T细胞注射液药品注册上市许可申请获受理
华东医药(000963.SZ):索米妥昔单抗注射液上市许可申请获得批准
智通财经 · 11-27
华东医药(000963.SZ):索米妥昔单抗注射液上市许可申请获得批准
华东医药(000963.SZ):注射用利纳西普上市许可申请获得批准
智通财经 · 11-27
华东医药(000963.SZ):注射用利纳西普上市许可申请获得批准
华东医药最新公告:全资子公司收到药品注册证书
证券之星 · 11-27
华东医药最新公告:全资子公司收到药品注册证书
加载更多
公司概况
公司名称:
华东医药股份有限公司
所属行业:
零售业
上市日期:
2000-01-27
主营业务:
华东医药股份有限公司主营业务是药品的研发、生产和销售。主要产品包括医药工业、医药商业、医美、工业微生物。公司医药工业深耕于专科,慢病用药及特殊用药领域的研发,生产和销售,并形成以慢性肾病,移植免疫,内分泌,消化系统等领域为主的核心产品管线。公司连续第十四年上榜财富中文网评选的《财富》中国500强,位列357位;入选米内网“2021年度中国医药工业百强”系列榜单,蝉联2021年度中国化药百强企业TOP10;荣膺全国工商联“2021年度中国医药制造业百强”“2021年度中国医药商业百强”,中国企业联合会“2022中国民营企业500强”“2022中国服务业企业500强”,荣获药智网“2022中国药品研发综合实力排行榜TOP100”“2022中国化药研发实力排行榜TOP100”。
发行价格:
5.76
{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"华东医药","latestPrice":36.19,"timestamp":1734591780000,"preClose":35.99,"halted":0,"volume":7709824,"delay":0,"floatShares":1752000000,"shares":1754000000,"eps":1.8311,"marketStatus":"已收盘","marketStatusCode":5,"change":0.2,"latestTime":"12-19 15:00:00","open":35.9,"high":36.24,"low":35.61,"amount":277000000,"amplitude":0.0175,"askPrice":36.19,"askSize":24,"bidPrice":36.17,"bidSize":14,"shortable":0,"etf":0,"ttmEps":1.8311,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"adjPreClose":35.99,"symbolType":"stock","openAndCloseTimeList":[[1734571800000,1734579000000],[1734584400000,1734591600000]],"highLimit":39.59,"lowLimit":32.39,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1754262548,"pbRate":2.86,"roa":"--","roe":"11.7%","epsLYR":1.6219,"committee":-0.154446,"marketValue":63487000000,"floatMarketCap":63411000000,"peRate":19.764076,"changeRate":0.0056,"turnoverRate":0.0044,"status":0},"requestUrl":"/m/hq/s/000963","defaultTab":"news","newsList":[{"id":"2492820991","title":"翰森制药与默沙东达成20亿美元合作,恒瑞医药1类新药获批临床,华东医药1类新药获美FDA批准临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2492820991","media":"谈医说药","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492820991?lang=zh_cn&edition=full","pubTime":"2024-12-18 23:06","pubTimestamp":1734534379,"startTime":"0","endTime":"0","summary":"默沙东预计产生1.12亿美元或每股0.04美元的税前费用,将计入2024年第四季度通用及非通用会计准则财务数据。有效期自批准之日起至2029年12月16日。上海医药:公司开发的“I48”临床试验申请收到国家药监局核准签发的《药物临床试验批准通知书》。本次获得临床试验批准通知书,对公司经营情况无重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218231451ab821b0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218231451ab821b0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064130708.USD","BK0187","BK0239","LU2488822045.USD","BK0028","BK0060","03692","BK0132","LU1064131003.USD","LU2328871848.SGD","BK0209","600276","BK0188","LU1969619763.USD","BK0175","BK0196","LU2148510915.USD","LU0405327148.USD","MRK","LU0405327494.USD","000963","LU1328615791.USD","BK0012","BK0183"],"gpt_icon":0},{"id":"2492297714","title":"华东医药(000963.SZ):HDM1005注射液药品临床试验申请获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2492297714","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492297714?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:28","pubTimestamp":1734514106,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华东医药 发布公告,2024年12月17日,公司全资子公司杭州中美华东制药有限公司收到美国食品药品监督管理局通知,由中美华东申报的HDM1005注射液药品临床试验申请已获得美国FDA批准,可在美国开展I期临床试验。本次HDM1005注射液临床试验获批,是该款产品研发进程中的又一重要进展,将进一步提升公司在内分泌治疗领域的核心竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK0209","LU2328871848.SGD","BK1583","000963","BK0183","BK0187","BK1576","BK0196","BK1141","03347","BK0132","BK0188","LU1969619763.USD"],"gpt_icon":0},{"id":"2491500803","title":"华东医药(000963)106.37万股限售股将于12月16日解禁,占总股本0.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491500803","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491500803?lang=zh_cn&edition=full","pubTime":"2024-12-16 08:02","pubTimestamp":1734307342,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,华东医药于12月16日将有106.37万股限售股份解禁,为公司股权激励限售股份,占公司总股本0.06%。最近一年内,该股累计解禁19.25万股,占总股本的0.01%。本次解禁后,公司还有210.23万股限售股份,占总股本0.12%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121600001190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","LU1969619763.USD","BK0175","LU2328871848.SGD","BK0183","BK0187","BK0188","BK0196","BK0209","BK0132"],"gpt_icon":0},{"id":"2490608330","title":"华东医药(000963.SZ):注射用利纳西普用于治疗复发性心包炎上市许可申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2490608330","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490608330?lang=zh_cn&edition=full","pubTime":"2024-12-10 18:01","pubTimestamp":1733824907,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华东医药(000963.SZ)公告,公司全资子公司杭州中美华东制药有限公司(简称“中美华东”)收到国家药品监督管理局(NMPA)核准签发的《药品注册证书》,由中美华东申报的注射用利纳西普用于治疗复发性心包炎(RP)的上市许可申请获得批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","000963","LU2328871848.SGD","BK0188","BK0175","BK0132","BK0196","BK0209","BK0187","LU1969619763.USD"],"gpt_icon":0},{"id":"2490060925","title":"华东医药最新公告:全资子公司收到注射用利纳西普药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2490060925","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490060925?lang=zh_cn&edition=full","pubTime":"2024-12-10 18:00","pubTimestamp":1733824818,"startTime":"0","endTime":"0","summary":"华东医药公告,公司全资子公司中美华东收到国家药品监督管理局核准签发的《药品注册证书》,注射用利纳西普用于治疗复发性心包炎的上市许可申请获得批准。该药物为中美华东与美国上市公司Kiniksa Pharmaceuticals, Ltd.合作开发,中美华东拥有该产品在中国等24个亚太国家和地区的独家许可。本次获批上市将为国内RP患者带来新的治疗选择。公司在注射用利纳西普项目的研发直接投入约为9870万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121000035430.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0183","BK0188","LU2328871848.SGD","LU1969619763.USD","BK0209","BK0187","000963","BK0196","BK0132"],"gpt_icon":0},{"id":"2488169589","title":"华东医药:关于监事辞职暨补选监事的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2488169589","media":"新浪财经-鹰眼工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488169589?lang=zh_cn&edition=full","pubTime":"2024-12-04 19:00","pubTimestamp":1733310000,"startTime":"0","endTime":"0","summary":"华东医药股份有限公司关于监事辞职暨补选监事的公告本公司及监事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或重大遗漏。本次补选监事事项尚需提交公司股东大会审议通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-12-04/doc-incyhynk7373473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0187","BK0132","BK0188","LU1969619763.USD","000963","LU2328871848.SGD","BK0175","BK0196","BK0209","BK0183"],"gpt_icon":0},{"id":"2488951803","title":"概念掘金 | 医药巨头在华新建胰岛素生产基地,这些公司或成为“赢家”","url":"https://stock-news.laohu8.com/highlight/detail?id=2488951803","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488951803?lang=zh_cn&edition=full","pubTime":"2024-12-03 10:11","pubTimestamp":1733191895,"startTime":"0","endTime":"0","summary":"创造了公司在华最大单笔投资记录","market":"hk","thumbnail":"https://img3.gelonghui.com/02fa1-16106239-1718-4fab-8750-6efec1b6d747.jpg?guru_height=3672&guru_width=5184","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/02fa1-16106239-1718-4fab-8750-6efec1b6d747.jpg?guru_height=3672&guru_width=5184"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1419204","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0175","BK0209","BK1574","BK0028","BK0132","BK0239","LU1064131003.USD","LU1969619763.USD","603087","600276","BK0012","BK1515","BK0188","09939","LU2328871848.SGD","LU1064130708.USD","BK1161","BK0187","LU2488822045.USD","LU1328615791.USD","600867","BK0060","BK0196","LU2148510915.USD","000963","601089","BK0183","LU0405327148.USD","LU0405327494.USD"],"gpt_icon":0},{"id":"2488692678","title":"华东医药(000963.SZ):乌司奴单抗注射液用于儿童斑块状银屑病的补充申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2488692678","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488692678?lang=zh_cn&edition=full","pubTime":"2024-12-02 19:54","pubTimestamp":1733140442,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华东医药(000963.SZ)发布公告,2024年12月2日,公司全资子公司杭州中美华东制药有限公司(“中美华东”)收到国家药品监督管理局(NMPA)签发的《受理通知书》(受理号:CYSB2400311),由中美华东申报的乌司奴单抗注射液(研发代码:HDM3001/QX001S)用于儿童斑块状银屑病的补充申请获得受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0175","BK0188","LU1969619763.USD","BK0187","BK0196","LU2328871848.SGD","BK0132","BK0209","000963"],"gpt_icon":0},{"id":"2488620833","title":"华东医药最新公告:乌司奴单抗注射液儿童斑块状银屑病补充申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2488620833","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488620833?lang=zh_cn&edition=full","pubTime":"2024-12-02 19:19","pubTimestamp":1733138368,"startTime":"0","endTime":"0","summary":"华东医药公告,全资子公司杭州中美华东制药有限公司收到国家药品监督管理局签发的《受理通知书》,乌司奴单抗注射液用于儿童斑块状银屑病的补充申请获得受理。该药物为原研产品Stelara 的生物类似药,规格为预充式注射器:45mg/支,适用于对其他系统性治疗或光疗应答不足或无法耐受的6岁及以上儿童和青少年中重度斑块状银屑病患者。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120200026580.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","000963","LU2328871848.SGD","BK0188","BK0175","BK0132","BK0196","BK0209","BK0187","LU1969619763.USD"],"gpt_icon":0},{"id":"2487536352","title":"华东医药(000963.SZ):中美华东部分产品纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2487536352","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487536352?lang=zh_cn&edition=full","pubTime":"2024-11-29 17:42","pubTimestamp":1732873360,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华东医药 发布公告,11月28日,国家医保局、人力资源社会保障部发布《关于印发<国家基本医疗保险、工伤保险和生育保险药品目录>的通知》,公司部分产品被纳入《2024年国家医保目录》。公司全资子公司杭州中美华东制药有限公司2024年新上市药品乌司奴单抗注射液属于《2024年国家医保目录》协议期内谈判药品部分,他克莫司颗粒被纳入《2024年国家医保目录》竞价药品部分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1218051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","000963","BK0183","BK0188","BK0196","BK0175","BK0209","LU1969619763.USD","BK0187","LU2328871848.SGD"],"gpt_icon":0},{"id":"2487047933","title":"《股市简讯》中国华东医药劲扬超7%,子公司获得FDA新药临床试验批准通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2487047933","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487047933?lang=zh_cn&edition=full","pubTime":"2024-11-29 13:25","pubTimestamp":1732857929,"startTime":"0","endTime":"0","summary":"《股市简讯》中国华东医药劲扬超7%,子公司获得FDA新药临床试验批准通知* 中国华东医药000963.SZ周五劲扬超7%。* 公司公告称,全资子公司中美华东获得美国FDA新药临床试验批准通知,由中美华东申报的HDM1005注射液药品临床试验申请已获得美国FDA批准,可在美国开展I期临床试验。(完) 更多股市简讯请点选CN-CMN-HOT (发稿 刘珞焱;审校 杨淑祯) ((luoyan.liu@tr.com; +86 021 2083 0166;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241129:nL3S3N00CQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK0188","LU2328871848.SGD","BK0132","BK0196","BK0209","BK0183","LU1969619763.USD","000963","BK0175"],"gpt_icon":0},{"id":"2486636063","title":"华东医药(000963.SZ):中美华东HDM1005注射液获得美国FDA新药临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2486636063","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486636063?lang=zh_cn&edition=full","pubTime":"2024-11-28 17:11","pubTimestamp":1732785103,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华东医药 发布公告,2024年11月28日,公司全资子公司杭州中美华东制药有限公司收到美国食品药品监督管理局通知,由中美华东申报的HDM1005注射液药品临床试验申请已获得美国FDA批准,可在美国开展I期临床试验。临床前研究和已有的临床I期数据显示,HDM1005具有显著的减重效果;具有改善OSA合并肥胖或超重患者相关症状的潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217265.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK0188","BK0196","BK1576","BK0183","LU1969619763.USD","BK0175","03347","000963","BK1141","LU2328871848.SGD","BK1583","BK0132","BK0209"],"gpt_icon":0},{"id":"2486398360","title":"华东医药最新公告:全资子公司中美华东获得美国FDA新药临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2486398360","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486398360?lang=zh_cn&edition=full","pubTime":"2024-11-28 17:09","pubTimestamp":1732784975,"startTime":"0","endTime":"0","summary":"华东医药公告,全资子公司中美华东收到美国FDA通知,HDM1005注射液药品临床试验申请已获得美国FDA批准,可在美国开展I期临床试验。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112800027715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","LU1969619763.USD","BK0196","BK1576","LU2328871848.SGD","BK0188","000963","BK1583","BK0183","03347","BK0187","BK0209","BK0175","BK0132"],"gpt_icon":0},{"id":"2486362028","title":"11月28日华东医药现1笔大宗交易 机构净买入204.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486362028","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486362028?lang=zh_cn&edition=full","pubTime":"2024-11-28 16:43","pubTimestamp":1732783411,"startTime":"0","endTime":"0","summary":"证券之星消息,11月28日华东医药发生大宗交易,交易数据如下:大宗交易成交价格36.5元,成交5.6万股,成交金额204.4万元,买方营业部为机构专用,卖方营业部为中信证券股份有限公司上海分公司。近三个月该股共发生1笔大宗交易,合计成交560.0手。截至2024年11月28日收盘,华东医药报收于36.5元,上涨0.55%,换手率1.14%,成交量20.0万手,成交额7.41亿元。该股最近90天内共有20家机构给出评级,买入评级17家,增持评级3家;过去90天内机构目标均价为44.69。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112800025784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0183","BK0188","LU2328871848.SGD","LU1969619763.USD","BK0209","BK0187","000963","BK0196","BK0132"],"gpt_icon":0},{"id":"2486215357","title":"华东医药两款创新药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2486215357","media":"市场资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486215357?lang=zh_cn&edition=full","pubTime":"2024-11-28 12:35","pubTimestamp":1732768500,"startTime":"0","endTime":"0","summary":"11月27日,国家药监局网站显示,华东医药的两款创新药获批上市,一款为索米妥昔单抗,另一款为利纳西普。2022年11月,索米妥昔单抗凭借单臂III期SORAYA研究的积极结果获FDA加速批准上市,商品名为Elahere。2008年2月,Rilonacept获FDA批准上市,商品名为Arcalyst。今年3月,华东医药也提交了Rilonacept治疗RP的新适应症上市申请。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-28/doc-incxquyv3047397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK0209","06978","BK0187","BK0196","LU2328871848.SGD","BK0188","BK0132","LU1969619763.USD","BK1161","000963","BK0175","BK1574","BK0183"],"gpt_icon":0},{"id":"2486335803","title":"《股市简讯》杭州九源基因香港“首秀”急挫四成,尽管公开发售超额675倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2486335803","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486335803?lang=zh_cn&edition=full","pubTime":"2024-11-28 11:58","pubTimestamp":1732766282,"startTime":"0","endTime":"0","summary":"《股市简讯》杭州九源基因香港“首秀”急挫四成,尽管公开发售超额675倍* 中国生物制药公司--杭州九源基因工程2566.HK周四香港联交所首日挂牌,盘中一度低探7.5港元,较招股价急挫四成;随后跌幅稍为收窄。* 该公司以接近招股价区间顶端的12.42港元定价,集资5.6亿港元,面向散户的公开发售部分录得675倍超额认购,面向机构投资者的国际发售则超额0.2倍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"68d519ec007bd04065c3224a9b78538f","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241128:nL3T3MZ09G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0003895053.USD","LU0048580855.USD","BK0096","LU0307460666.USD","BK1191","00241","LU1969619763.USD","HK0000320264.USD","SG9999006514.SGD","600196","000963","IE00B0JY6N72.USD","LU1048596156.SGD","LU1328277881.USD","BK1189","BK1575","00656","LU0634319403.HKD","LU1481107354.HKD","SG9999000459.SGD","BK0132","IE00BZ08YT58.USD","LU1981816686.USD","LU1044875133.USD","BK1593","LU2293587155.HKD","BK4533","02566","BK0209","02196","BK4581","LU0067412154.USD","LU0593848301.USD","89988","LU0640798160.USD","LU1188198961.HKD","BK4527","LU0011963245.USD","LU0327786744.USD","LU0868486357.SGD","LU0231483743.USD","LU1282649067.USD","LU0463099449.HKD","LU0543330483.HKD","LU0314109678.HKD","LU1303224171.USD","HBBD.SI","LU1048484197.HKD"],"gpt_icon":1},{"id":"2486849623","title":"华东医药(000963.SZ):IM19嵌合抗原受体T细胞注射液药品注册上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2486849623","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486849623?lang=zh_cn&edition=full","pubTime":"2024-11-27 18:21","pubTimestamp":1732702881,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华东医药 发布公告,2024年11月27日,公司全资子公司华东医药(杭州)有限公司独家商业化的靶向CD19的自体CAR-T候选产品,IM19嵌合抗原受体T细胞注射液的药品注册上市许可申请获国家药品监督管理局受理。IM19 CAR-T细胞注射液注册上市许可申请的受理,是基于一项在中国进行的开放标签、单臂、多中心I/II期的临床试验。研究结果显示, IM19 CAR-T细胞注射液针对复发或难治CD19阳性的非霍奇金淋巴瘤,具有良好的疗效和安全性效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1216733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1969619763.USD","BK0196","BK0132","BK0187","BK0209","LU2328871848.SGD","BK0188","BK0175","000963","BK0183"],"gpt_icon":0},{"id":"2486884962","title":"华东医药(000963.SZ):索米妥昔单抗注射液上市许可申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2486884962","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486884962?lang=zh_cn&edition=full","pubTime":"2024-11-27 18:17","pubTimestamp":1732702657,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华东医药 发布公告,2024年11月27日,公司全资子公司杭州中美华东制药有限公司收到国家药品监督管理局核准签发的《药品注册证书》,中美华东申报的索米妥昔单抗注射液用于既往接受过1-3线系统性治疗的叶酸受体α阳性的铂类耐药卵巢癌适应症的上市许可申请获得批准。2022年5月,ImmunoGen宣布美国FDA已受理该产品的生物制品许可申请,并授予优先审评资格。2022年11月,ImmunoGen宣布该产品获得美国FDA加速批准上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1216730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0187","BK0175","LU2328871848.SGD","BK0196","BK0188","000963","BK0209","BK0132","LU1969619763.USD"],"gpt_icon":0},{"id":"2486849369","title":"华东医药(000963.SZ):注射用利纳西普上市许可申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2486849369","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486849369?lang=zh_cn&edition=full","pubTime":"2024-11-27 18:14","pubTimestamp":1732702485,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华东医药 发布公告,11月27日,公司全资子公司杭州中美华东制药有限公司收到国家药品监督管理局核准签发的《药品注册证书》,由中美华东注册代理申报的注射用利纳西普的上市许可申请获得批准,用于治疗成人和12岁及以上青少年冷吡啉相关周期性综合征,包括家族性寒冷性自身炎症综合征和Muckle-Wells综合征。2020年,FDA批准其用于治疗IL-1受体拮抗剂缺乏症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1216725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","LU1969619763.USD","BK0187","BK0196","BK0132","LU2328871848.SGD","000963","BK0209","BK0183","BK0188"],"gpt_icon":0},{"id":"2486496778","title":"华东医药最新公告:全资子公司收到药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2486496778","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486496778?lang=zh_cn&edition=full","pubTime":"2024-11-27 18:10","pubTimestamp":1732702256,"startTime":"0","endTime":"0","summary":"华东医药公告,供公司全资子公司中美华东收到国家药品监督管理局核准签发的《药品注册证书》,注射用利纳西普(商品名:炎朵®/ARCALYST®)的上市许可申请获得批准,用于治疗成人和12岁及以上青少年冷吡啉相关周期性综合征(CAPS),包括家族性寒冷性自身炎症综合征(FCAS)和Muckle-Wells综合征(MWS)。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112700031328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0132","BK0188","LU1969619763.USD","000963","LU2328871848.SGD","BK0175","BK0196","BK0209","BK0183"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","stockEarnings":[{"period":"1week","weight":-0.0291},{"period":"1month","weight":0.0204},{"period":"3month","weight":0.3218},{"period":"6month","weight":0.2644},{"period":"1year","weight":-0.0694},{"period":"ytd","weight":-0.1045}],"companyName":"华东医药股份有限公司","boardCode":"AI0052","perCapita":"19070股","boardName":"零售业","registeredCapital":"175426万元","compareEarnings":[{"period":"1week","weight":-0.0146},{"period":"1month","weight":0.0176},{"period":"3month","weight":0.2362},{"period":"6month","weight":0.1281},{"period":"1year","weight":0.1534},{"period":"ytd","weight":0.1369}],"survey":" 华东医药股份有限公司主营业务是药品的研发、生产和销售。主要产品包括医药工业、医药商业、医美、工业微生物。公司医药工业深耕于专科,慢病用药及特殊用药领域的研发,生产和销售,并形成以慢性肾病,移植免疫,内分泌,消化系统等领域为主的核心产品管线。公司连续第十四年上榜财富中文网评选的《财富》中国500强,位列357位;入选米内网“2021年度中国医药工业百强”系列榜单,蝉联2021年度中国化药百强企业TOP10;荣膺全国工商联“2021年度中国医药制造业百强”“2021年度中国医药商业百强”,中国企业联合会“2022中国民营企业500强”“2022中国服务业企业500强”,荣获药智网“2022中国药品研发综合实力排行榜TOP100”“2022中国化药研发实力排行榜TOP100”。","serverTime":1734599574723,"listedPrice":5.76,"stockholders":"91879人(较上一季度减少6.53%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华东医药,000963,华东医药股票,华东医药股票老虎,华东医药股票老虎国际,华东医药行情,华东医药股票行情,华东医药股价,华东医药股市,华东医药股票价格,华东医药股票交易,华东医药股票购买,华东医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}